ERLYAND, JANSSEN APALUTAMIDE (Janssen-Cilag Pty Ltd)
Product name
ERLYAND, JANSSEN APALUTAMIDE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
apalutamide
Registration type
EOI
Indication
ERLYAND, JANSSEN APALUTAMIDE (film coated tablet) is now also indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).